‘gets stronger‘ And ‘Trodelvy‘are two medicines for him metastatic breast cancer and from now on it will be on the list of care financed by Social Security. It is estimated that around 2,000 women will benefit from these treatments each year.
‘Enhertu’ is indicated for the Unresectable or metastatic HER2-positive breast cancer who have received one or more prior HER2 targeted regimens. Contains as an active ingredient trastuzumab deruxtecan.
‘Trodelvy’ contains as an active ingredient sacituzumab govitecan and is indicated for the treatment of patients with Unresectable or metastatic triple negative breast cancer who have received two or more prior systemic therapies, including at least one for advanced disease
without your prior and express consent.
To date, both drugs were accessible through access to drug programs in special situationsmanaged by the Spanish Agency for Medicines and Health Products.
Now an agreement has been reached with the Inter-ministerial commission on drug pricescomposed of representatives of the various Ministries and of all the Autonomous Communities, and with this pact the door opens to the incorporation of these two medicines in the pharmaceutical provision of the SNS as soon as the agreement is formalized and inserted in the nomenclature, as of December .
